Table 5.

Management and outcomes of all available reported liver transplant recipients infected with COVID-19.

Study	ISM management	COVID-19 targeted management	ICU	Complications	Outcome
Zhong	Tac held; IVMP	Oseltamivir, Abx,	Yes	None	Recovered, 40d
Liu	Tac held; IVMP	Umifenovir, lopinavir/ritonavir, IVIG, Abx, INF-a	No	None	Recovered, 35d
Huang	Reduced Tac, MMF; IVMP	Umifenovir, lopinavir/ritonavir, Abx, INF-a		Respiratory failure, AKI, MOF,	Died, 45d
Qin	No change	Oseltamivir, IVIG, rh-GCSF, Abx			Recovered, 53d
Morand	Reduced Tac	Paracetamol			Recovered, 11d
Lagana	Reduced MMF	Hydroxychloroquine	Yes	None	Hospitalized, 16d
Kates	No change		Yes	AKI	Recovered, 6d
Hammami	No change	Hydroxychloroquine, Azithromycin, Abx, tocilizumab			Recovered, 16d
Fernández-Ruiz	Held EVE and start Tac, MMF	Hydroxychloroquine, lopinavir/ritonavir			Recovered, 19d
	Held EVE, MMF and start Tac	Hydroxychloroquine, lopinavir/ritonavir, IFN-b		AKI, ARDS,	Died, 7d
	No change	Hydroxychloroquine, IFN-b			Recovered, 14d
	Held MMF		Yes	ARDS, Refractory shock	Died, 24d
	No change	Hydroxychloroquine			Recovered, 15d
	No change				Recovered, 18d
Donato					6 Recovered, 2 Hospitalized